J Clin Aesthet Dermatol. 2024;17(12):16–17. by Roger I. Ceilley, MD, FAAD, FCMS, and Shandhan Sureshbabu, CDT Dr. Ceilley and Mr. Sureshbabu are with Dermatology P.C. in West Des Moines, Iowa. FUNDING: No funding was provided for this article. DISCLOSURES: The authors declare no conflicts of interest relevant to the content of this article. ABSTRACT: This article explains the value and rationale behind the use of checklists. Included is a surgery checklist used successfully over many years by a highly experienced dermatologist and dermatologic surgeon. This approach is used by all clinicians and office staff in a very busy ambulatory practice that incorporates medical, cosmetic, and surgical dermatology, including Mohs micrographic surgery. KEYWORDS: Dermatologic surgery, Mohs micrographic surgery, surgical dermatology, excision, biopsy, practice management Life and the practice of medicine are becoming increasingly complex. However, there is a straightforward method that can enhance t

J Clin Aesthet Dermatol. 2024;17(12):32–36. by Rohan Shankarghatta, MBBS, BSc*; Sarika Grover MBBS, BSc*; Julia Bahja, MBBS, MRes; Zeanab Chaer, BDS; Rahim Feddag, BDS; Can Celik, BDS; Felix Karst, MD, BDS, MRCS, AKC, and James Olding, MBBS, BDS, BSc, MRCS Dr. Shankarghatta is with the Manchester University NHS Foundation Trust in Manchester, United Kingdom. Dr. Grover is with the University Hospitals Coventry and Warwickshire NHS Trust in Coventry, United Kingdom. Dr. Bahja is with the Great Western Hospitals NHS Foundation Trust in Swindon, United Kingdom. Ms. Chaer and Mr. Feddag are with King’s College London, Faculty of Dentistry, Oral and Craniofacial Sciences in London, United Kingdom. Dr. Celik is with Queen Mary Barts and the London School of Medicine and Dentistry in London, United Kingdom. Dr. Karst is with Royal Free London NHS Foundation Trust in London, United Kingdom. Dr. Olding is with the Department of Oral and Maxillofacial Surgery at King’s College Hospital in London

J Clin Aesthet Dermatol. 2024;17(12):38–41. by Evgeniya Shelemba, MD, PhD, and Elena Rumyantseva Mathey, MD, PhD Dr. Shelemba is with P.L. Shupik National Medical Academy of Post-Graduate Education in Kyivska, Ukraine. Dr. Mathey is with the International Master Course on Aging Science in Paris, France. ABSTRACT: Background: Intradermal injections of highly diluted botulinic neuroprotein is a popular aesthetic medicine procedure to improve the texture of the skin, enlarged pores, and fine lines. Objective: The authors present a case report of nine subjects who received treatment with botulinic neuroprotein combined with an amino acid cluster and low molecular weight hyaluronic acid. Methods: Nine women between the ages of 30 to 59 years old in a stable medical condition with moderate to severe lateral cantal wrinkles and smile lines at maximum expression and were recruited. The typical exclusion criteria for botulinum neurotoxin and hyaluronic acid injections were fulfilled. Results: N

J Clin Aesthet Dermatol. 2024;17(11):17–22. by Sheetal Sapra, MD, FRCPC; Jennifer VH Tran, BSc; Harmeet Gurm, MSc; and Mackenzie Eleuterio, BSc All authors are affiliated with the Institute of Cosmetic and Laser Surgery in Oakville, Ontario, Canada. FUNDING: No funding was provided for this article. DISCLOSURES: The authors report no conflicts of interest relevant to the content of this article. ABSTRACT: Objective. We sought to analyze the effectiveness, recurrence, safety, and patient satisfaction rates following xanthelasma palpebrarum (XP) treatment with trichloroacetic acid (TCA) 80%. Methods: This was a retrospective review of patients treated with TCA 80% for XP between January 2012 and August 2022. A prospective telephone questionnaire was administered to the same patient population to evaluate recurrence, patient satisfaction, and side effects. Results: In total, 77 patients were included in this retrospective review.  Most patients received one treatment (n=38; 49.4%) and had

J Clin Aesthet Dermatol. 2024;17(11):24–30. by Glynis Ablon, MD, FAAD Dr. Ablon is with the Ablon Skin Institute and Research Center in Manhattan Beach, California. FUNDING: This study was sponsored by VitaMedica, the manufacturer of the study product.  DISCLOSURES: The author reports no conflicts of interest relevant to the content of this article. Abstract: Background: Acne vulgaris is a chronic, inflammatory skin disease of the pilosebaceous unit frequently cited as the most common condition diagnosed and treated by dermatologists. Among the many therapies developed for treating acne, none are effective for all patients and new treatments are always being sought. A commercial nutraceutical formulated with vitamins, minerals and a proprietary blend of botanicals has been used as a safe and effective adjunctive therapy for non-cystic acne (Clear Skin Formula; VitaMedica®). Objective: The objective of this study was to evaluate the safety and efficacy of this nutraceutical for treating